2001 Press Releases Communiqués de presse

November 27, 2001 27 November, 2001

Pheromone Sciences Corp. On Track and Moving Forward

November 5, 2001 5 November, 2001

Pheromone Sciences' PSC Fertility Monitor™ U.S. Trial Reaches Full Enrollment

October 15, 2001 15 October, 2001

Pheromone Sciences Corp. Receives European Regulatory Approval

September 4, 2001 4 September, 2001

Pamela Wallin Appointed to Pheromone Sciences Board of Directors

June 5, 2001 5 June, 2001

Pheromone Sciences appoints Chief Financial Officer

May 22, 2001 22 May, 2001

Pheromone Sciences Pivotal Trial Patient Recruitment Underway Results Expected During Q-4

April 12, 2001 12 April, 2001

Pheromone Sciences Corp. Receives Final Clearance on Prospectus

April 10, 2001 10 April, 2001

Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial

April 10, 2001 10 April, 2001

Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial

March 13, 2001 13 March, 2001

Pheromone Sciences Initiates Veterinary Program

March 13, 2001 13 March, 2001

Pheromone Sciences Initiates Veterinary Program

March 5, 2001 5 March, 2001

Pheromone Sciences Corp's President and CEO, Christopher Neuman, Featured on ROB TV

March 5, 2001 5 March, 2001

Pheromone Sciences Corp's President and CEO, Christopher Neuman, Featured on ROB TV

February 26, 2001 26 February, 2001

Pheromone Sciences Corp. Completes Private Placement

February 15, 2001 15 February, 2001

Eldon Smith MD Appointed to Pheromone Sciences Board of Directors

February 14, 2001 14 February, 2001

Pheromone Sciences Corp Adds Half Warrant To Offering Pheromone Sciences Corp Adds Half Warrant To Offering

February 13, 2001 13 February, 2001

Benoit La Salle Joins Pheromone Sciences Board of Directors Benoit La Salle Joins Pheromone Sciences Board of Directors

February 8, 2001 8 February, 2001

Pheromone Sciences Corp Announces U.S. Clinical Trials

January 22, 2001 22 January, 2001

Pheromone Sciences Corp. Announces Private Placement Offering

January 17, 2001 17 January, 2001

Pheromone Sciences Corp Announces Positive Clinical Trial Results

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 27, 2001 27 November, 2001

Pheromone Sciences Corp. On Track and Moving Forward


Toronto, Ontario (November 27, 2001) -- Dr. William Cochrane, Chairman of the Board and Mr. Chris Neuman, President & CEO of Pheromone Sciences Corp (CDNX:PHS), today stated that there are no corporate developments that would account for the recent change in the company's share price. They further stated that the Company continues to achieve its planned milestones with timelines remaining intact to deliver U.S. clinical trial results and a subsequent FDA submission early in 2002.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 05, 2001 5 November, 2001

Pheromone Sciences' PSC Fertility Monitor™ U.S. Trial Reaches Full Enrollment


Pheromone Sciences Corp. (PHS: CDNX), today announced that it has achieved full enrollment of its USA based multi-center clinical trial for the PSC Fertility Monitor�¢ï¿½�¢.

The clinical trial, designed to test the efficacy of the PSC Fertility Monitor, is being carried out at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at the Women's Institute for Fertility, Endocrinology and Menopause in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology, Thomas Jefferson University Hospital.

"With the trial now fully enrolled, we intend to insure timely completion, data analysis, and reporting of results," said Christopher Neuman, President and CEO of Pheromone Sciences. "Results similar to those previously reported from the University of Toronto would provide the data required for marketing approval in the U.S."

Frost and Sullivan in their October 2001 report titled, Innovative Medical Devices Straight from Science Fiction wrote In North America, medical devices and technologies are converging to revolutionize the consumer self-care market". Mr. Neuman goes on to state, "Our PSC Fertility Monitor is one such example of this marriage of biotechnology and diagnostics to provide women with a reliable predictive approach to natural, cycle based family planning designed in a small wrist-watch sized device".

Subject to FDA approval, the PSC Fertility Monitor will be positioned in a marketplace of more than 5 million women across North America who are trying to conceive providing them with a personally customized, highly advanced diagnostic tool that can be used to provide up to 4 days advance notice of their pending ovulation. With this degree of advance notice, a women's ability to become pregnant increases significantly as most of the guesswork concerning timing of sexual relations to conceive can now be managed.

It is anticipated that many of the women currently using urine strips and basal temperature methods to determine their ovulation date would find the PSC Fertility Monitor appealing based on its ability to provide increased advance notice (4 days), ease of use, and non invasive approach.

"We are very pleased with the progress to date for this product. With the completion of the enrollment for the multi center trial coupled with the recent securing of the CE mark, the future marketability in North America and Europe for the PSC Fertility Monitor becomes more assured", stated Neuman.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 15, 2001 15 October, 2001

Pheromone Sciences Corp. Receives European Regulatory Approval


CE Mark provides gateway to European Marketplace for PSC Fertility Monitor�¢ï¿½�¢

Pheromone Sciences Corp (CDNX:PHS), today announced that it has received CE mark regulatory approval for its PSC Fertility Monitor�¢ï¿½�¢. The CE Mark provides a regulatory gateway to the European marketplace thereby allowing the Company to proceed to attract licensees for marketing and distribution rights to the device in the various member countries of the European Community. It enables the Company to market the PSC Fertility Monitor�¢ï¿½�¢ without having to undergo country specific registration.

"We are excited about this as it represents an important step in the Company's product development plans" said Christopher Neuman, President & CEO of Pheromone. "With this approval, our potential market has been broadened which no doubt will lead to increased revenue."

As part of its strategy to make the PSC Fertility Monitor�¢ï¿½�¢ available to women who would value the convenience of use and advance notice of their peak fertility and ovulation days, the company had conducted the prerequisite testing required to file for the CE mark as a first step in bringing the PSC Fertility Monitor to the European Market.

The PSC Fertility Monitor�¢ï¿½�¢ offers a new user- friendly option in family planning. This product, which is housed in a modern styled wristwatch like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility Monitor�¢ï¿½�¢ is a proprietary, non- invasive device which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor enabling it to take up to 12 daily measurements from the skin surface and to evaluate the data in order to predict the status of the user, with 4 days advance notice, as being not-fertile, fertile or ovulating. Results can be viewed at any time on the LCD screen of the device or as a computer- generated graphical printout for medical professionals.

"This is a great opportunity. We are currently in discussions with several companies about licenses. These companies are well established firms that have the knowledge and understanding of the European Market that will help us market and distribute the PSC Fertility Monitor�¢ï¿½�¢ widely in this new area" said Neuman.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

INVESTOR CONTACT

Lorne Woods 1(800) 937-3095 investor@pheromonesciences.com http://www.pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 04, 2001 4 September, 2001

Pamela Wallin Appointed to Pheromone Sciences Board of Directors


Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Ms. Pamela Wallin, renowned Canadian journalist, broadcaster and businesswoman, to its Board of Directors.

Ms. Wallin brings a wealth of knowledge to the Pheromone Sciences' Board of Directors given her long- standing interest in women's health issues and an outstanding media career that has spanned some twenty- five years. Television journalist and author, Ms. Wallin currently hosts Pamela Wallin's Talk TV for the CTV group. Her latest book, Speaking of Success: Collected Wisdom, Insights and Reflections is scheduled to be published in September. Ms. Wallin has garnered a long list of awards during her career including the United Nations UNIFEM Canada Award for outstanding contributions toward the advancement of women and the Saskatchewan Order of Merit, the provinces highest honour to thank those who have dedicated their lives to improving their communities.

Ms. Wallin is very active in community affairs. Amongst her activities she currently sits on the Board of Directors of the University Health Network in Toronto, the Board of Governors of the University of Waterloo and she is a patron of the Genesis Research Foundation, Advancing Women's Health. She was educated at the University of Regina receiving an honours degree in psychology and political science and has since been awarded honorary degrees from the University of Western Ontario, Ryerson Polytechnic University, Wilfrid Laurier University and Loyalist College.

"Ms. Wallin is a wonderful addition to the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Through a combination of media experience, entrepreneurship and public policy interest that is unmatched in Canada, Pamela will bring a broader perspective to the Company."

The appointment, which is subject to regulatory approval, is part of an ongoing program to enhance the independent nature of the Board.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 05, 2001 5 June, 2001

Pheromone Sciences appoints Chief Financial Officer


Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Larry Cooper C.A. as its Chief Financial Officer.

A Chartered Accountant and member of the both the Order of Chartered Accountants and the Canadian Institute of Chartered Accountants, Mr. Cooper brings an enviable mix of financial and business development experience to the Company. Most recently, Mr. Cooper served as the Chief Financial Officer and Chief Administrative Officer of The Canadian Institute, an international business service provider with offices located in London, New York & Toronto.

Prior thereto, he spent ten years (1988-1998) with Allergan Canada a multi-national pharmaceutical manufacturer of prescription and non- prescription healthcare products. During this timeframe Mr. Cooper spent the first six years as Chief Financial Officer and thereafter as both the Chief Financial Officer and the Director of Business Development

Additional experience includes financial roles at Spalding Canada (1984--1988) where he was Chief Financial Officer, United Tire and Rubber Company (1982- -1984) and as the Accounting Manager at ENS Biologicals Inc. Mr. Cooper received his Bachelor of Commerce (Honors) degree from The University of Toronto.

In commenting on the announcement, Mr. Neuman CEO said "Mr. Cooper's experience is ideally suited to the further development and implementation of Pheromone Sciences Corp's business strategy. We are delighted to have Larry join our team."

Mr. Cooper succeeds Mr. Barry Sadrehashemi C.A., who has faithfully and efficiently served Pheromone Sciences from his Calgary base during the Company's transition to a public entity and subsequent move to Toronto.

INVESTOR CONTACT

Lorne Woods 1-(800) 937-3095 investor@pheromonesciences.com www.pheromonesciences.com

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 22, 2001 22 May, 2001

Pheromone Sciences Pivotal Trial Patient Recruitment Underway Results Expected During Q-4


Pheromone Sciences Corp (CDNX: PHS), today announced that patient recruitment has commenced on schedule at the U.S. based multi-center efficacy trial of its PSC Fertility Monitor(tm).

The trial, to be carried out in 140 subjects, is taking place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient interest at both trial centers has been high with results expected during Q-4, 2001.

"We are very pleased that the interest to participate in this trial is so strong within our community ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non-invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favorably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

"We remain committed to our goal of completing this trial for the fall using the results to underpin submissions to the FDA for marketing approval prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "Positive results would pave the way for U.S. regulatory approval and subsequent commercialization".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 12, 2001 12 April, 2001

Pheromone Sciences Corp. Receives Final Clearance on Prospectus


Pheromone Sciences Corp. (CDNX:PHS) today announced that it has received final clearance of its prospectus relating to the $2.0 million special warrant private placement completed in late February.

Under the terms of the placement each special warrant of the Company will be converted, at no additional consideration, into one common share and one- half of a warrant. Each whole warrant will entitle the holder to purchase one common share of the Company at an exercise price of $1.25 per share until February 23, 2002.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 10, 2001 10 April, 2001

Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial


Pheromone Sciences Corp (CDNX: PHS), today announced that it has received approval for its multi-center efficacy clinical trial of the PSC Fertility Monitor(tm).

The trial, to be carried out in 140 subjects, will take place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient recruitment will commence later this month with the study scheduled to report in Q-4, 2001.

"With ever increasing numbers of women seeking assistance in order to achieve conception, the medical profession is constantly looking for innovative tools to assist in the process ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non- invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

"We remain committed to our goal of filing submissions with the FDA for marketing approval on the PSC Fertility Monitor' prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "To this end we will diligently continue efforts towards the receipt of U.S. regulatory approval and commercialization in 2002".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - April 10, 2001 10 April, 2001

Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial


Pheromone Sciences Corp (CDNX: PHS), today announced that it has received approval for its multi- center efficacy clinical trial of the PSC Fertility Monitor(tm).

The trial, to be carried out in 140 subjects, will take place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient recruitment will commence later this month with the study scheduled to report in Q-4, 2001.

"With ever increasing numbers of women seeking assistance in order to achieve conception, the medical profession is constantly looking for innovative tools to assist in the process ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non-invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

"We remain committed to our goal of filing submissions with the FDA for marketing approval on the PSC Fertility Monitor' prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "To this end we will diligently continue efforts towards the receipt of U.S. regulatory approval and commercialization in 2002".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 13, 2001 13 March, 2001

Pheromone Sciences Initiates Veterinary Program


Dr. Walter H. Johnson of the University of Guelph to lead Large Animal Breeding Research Effort

Pheromone Sciences Corp (CDNX: PHS), today announced that it has engaged the Ontario Veterinary College to carry out experiments into veterinary applications for its PSC Fertility Monitor(tm). The work will be carried out under the auspices of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, Professor of Theriogenology at the University of Guelph. The program will investigate the potential for expanding Pheromone's Fertility Monitor platform technology to new applications such as the prediction of estrus and ovulation of animals. Initial research will focus on large animals in a farm breeding situation.

Unmet needs exist in this area as evidenced by the North American dairy industry where dairy industry researchers estimate that U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. $400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

"During the coming year we look forward to working through the issues in order to pursue the optimum solution for these important veterinary applications," said Dr. Johnson "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America. Improvements achieved in dairy herds may also have implications for breeding challenges in other animals"

"Fertility and ovulation monitoring problems are not unique to the dairy industry. Horses, sheep, pigs, small, captive and exotic (zoo) animals face similar breeding problems", said Christopher Neuman, President and CEO of Pheromone Sciences Corp. "Adapting the PSC Fertility Monitor(tm) platform technology to serve the special fertility and ovulation detection breeding needs of these groups represent a vertical opportunity where we can capitalize on the knowledge base already acquired through the monitor's development process for human use."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 13, 2001 13 March, 2001

Pheromone Sciences Initiates Veterinary Program


Dr. Walter H. Johnson of the University of Guelph to lead Large Animal Breeding Research Effort

Pheromone Sciences Corp (CDNX: PHS), today announced that it has engaged the Ontario Veterinary College to carry out experiments into veterinary applications for its PSC Fertility Monitor(tm). The work will be carried out under the auspices of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, Professor of Theriogenology at the University of Guelph. The program will investigate the potential for expanding Pheromone's Fertility Monitor platform technology to new applications such as the prediction of estrus and ovulation of animals. Initial research will focus on large animals in a farm breeding situation.

Unmet needs exist in this area as evidenced by the North American dairy industry where dairy industry researchers estimate that U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. $400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

"During the coming year we look forward to working through the issues in order to pursue the optimum solution for these important veterinary applications," said Dr. Johnson "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America. Improvements achieved in dairy herds may also have implications for breeding challenges in other animals"

"Fertility and ovulation monitoring problems are not unique to the dairy industry. Horses, sheep, pigs, small, captive and exotic (zoo) animals face similar breeding problems", said Christopher Neuman, President and CEO of Pheromone Sciences Corp. "Adapting the PSC Fertility Monitor(tm) platform technology to serve the special fertility and ovulation detection breeding needs of these groups represent a vertical opportunity where we can capitalize on the knowledge base already acquired through the monitor's development process for human use."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 05, 2001 5 March, 2001

Pheromone Sciences Corp's President and CEO, Christopher Neuman, Featured on ROB TV


Pheromone Sciences Corp's President and CEO, Christopher Neuman, was featured on the Friday, March 2/01 "On The Money" segment of ROB TV. Mr. Neuman was interviewed discussing the anticipated milestones in 2001-2002 for Pheromone Sciences Corp, as well as the status of Pheromone's lead product, the PSC Fertility Monitor(TM).

Interview Highlights:

-Pheromone Sciences is developing a platform technology with multiple applications in the areas of human fertility and sexuality. -The Company's PSC Fertility Monitor is a fertility cycle monitoring device for the consumer and professional medical market. Pheromone Sciences is also working on other applications built on the fertility monitor technology platform in addition to exploring the potential of it's synthetic human pheromone analogue PSC Synchronin(TM) for pharmaceutical/therapeutic applications. -U.S. Clinical Trials at two leading academic centers: Duke University in Durham, North Carolina and Thomas Jefferson University Hospital in Philadelphia, Pa. have started. -Early revenue generation is achievable for its Fertility Monitor product line with FDA approval expected to be sought as a non-invasive medical device in the latter part of 2001.

The interview can be viewed on ROB TV's website at: http://www.ROBTV.com until Friday, March 9/01. Once on the website home page, to view Mr. Neuman's interview, please first click on "Past Programs" (on the upper left of the home page). Once in the Past Programs field, please scroll over to the Friday column and go down to the "On The Money" segment (2:00pm-3:00pm). By clicking on "Modem" or "High Speed", you will be able to view the full hour segment of "On The Money". Mr. Neuman's interview takes place during the time slot of 14:00 -- 21:00 minutes. Please note that in order to view this interview, you must have Real Player installed in your computer. There is a direct link for this download on the ROB TV website.

For further information, please contact: Christopher Neuman Ph: (416) 861-9854, ext. 226 Email: cneuman@pheromonesciences.com

Nick Borrelly Ph: (604) 872-2012 Email: nborrelly@pheromonesciences.com

Pheromone Sciences is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human fertility and sexuality.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 05, 2001 5 March, 2001

Pheromone Sciences Corp's President and CEO, Christopher Neuman, Featured on ROB TV


Pheromone Sciences Corp's President and CEO, Christopher Neuman, was featured on the Friday, March 2/01 "On The Money" segment of ROB TV. Mr. Neuman was interviewed discussing the anticipated milestones in 2001-2002 for Pheromone Sciences Corp, as well as the status of Pheromone's lead product, the PSC Fertility Monitor(TM).

Interview Highlights:

-Pheromone Sciences is developing a platform technology with multiple applications in the areas of human fertility and sexuality. -The Company's PSC Fertility Monitor is a fertility cycle monitoring device for the consumer and professional medical market. Pheromone Sciences is also working on other applications built on the fertility monitor technology platform in addition to exploring the potential of it's synthetic human pheromone analogue PSC Synchronin(TM) for pharmaceutical/therapeutic applications. -U.S. Clinical Trials at two leading academic centers: Duke University in Durham, North Carolina and Thomas Jefferson University Hospital in Philadelphia, Pa. have started. -Early revenue generation is achievable for its Fertility Monitor product line with FDA approval expected to be sought as a non-invasive medical device in the latter part of 2001.

The interview can be viewed on ROB TV's website at: http://www.ROBTV.com until Friday, March 9/01. Once on the website home page, to view Mr. Neuman's interview, please first click on "Past Programs" (on the upper left of the home page). Once in the Past Programs field, please scroll over to the Friday column and go down to the "On The Money" segment (2:00pm-3:00pm). By clicking on "Modem" or "High Speed", you will be able to view the full hour segment of "On The Money". Mr. Neuman's interview takes place during the time slot of 14:00 -- 21:00 minutes. Please note that in order to view this interview, you must have Real Player installed in your computer. There is a direct link for this download on the ROB TV website.

For further information, please contact: Christopher Neuman Ph: (416) 861-9854, ext. 226 Email: cneuman@pheromonesciences.com

Nick Borrelly Ph: (604) 872-2012 Email: nborrelly@pheromonesciences.com

Pheromone Sciences is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human fertility and sexuality.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 26, 2001 26 February, 2001

Pheromone Sciences Corp. Completes Private Placement


Pheromone Sciences Corp. (CDNX:PHS) today announced that it has completed a private placement of 2,000,000 special warrants of the Company at an issue price of $1.00 per special warrant. Each special warrant is exercisable, at no additional consideration, into one common share and one- half of a warrant. Each whole warrant will entitle the holder to purchase one common share of the Company at an exercise price of $1.25 per share for one year.

A prospectus has been filed to qualify the distribution of the common shares and warrants issuable upon the exercise of the special warrants and to abridge the one year hold period otherwise applicable.

The net proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 15, 2001 15 February, 2001

Eldon Smith MD Appointed to Pheromone Sciences Board of Directors


Toronto, Ontario (February 15, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Eldon R. Smith, MD, FRCP(C), FACC, to its Board of Directors.

Dr. Eldon Smith brings a wealth of knowledge in medical research and extensive healthcare experience to Pheromone Sciences Board of Directors. He is presently Professor at the University of Calgary Medical School, where he was formerly the Dean of the Faculty of Medicine, and previously head of the Department of Medicine and head of the Division of Cardiology. Dr. Smith is a leading clinician and research scientist who has made major contributions to the Canadian cardiology and medical communities. He has served as President of the Canadian Cardiovascular Society, Chairman of the Scientific Grant Review Committee of the Heart and Stroke Foundation, and President of the Association of Canadian Medical Colleges. He is currently a Trustee of the Alberta Heritage Foundation for Medical Research and a member of the Premier's Advisory Council on Health for the Province of Alberta. He is also President of the Peter Lougheed Medical Research Foundation.

In addition to his medical practice, Dr Smith serves on the Board of Directors of a number of public companies including Canadian Natural Resources Ltd, Vasogen Inc. and BioMax Technologies Inc. He also serves on the Advisory Boards of the Canadian Medical Discovery Fund and a number of Biotechnology and Pharmaceutical Companies.

"Dr. Smith is a powerful addition to the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Eldon brings a rare combination of clinical, medical and business experience. Eldon has been used extensively by several of Canada's top funds to evaluate and mentor companies from inception to commercialization."

The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Charles Borg PhD. Mr. Borg remains a member of senior management retaining the position Executive Vice- President and Chief Operating Officer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 14, 2001 14 February, 2001

Pheromone Sciences Corp Adds Half Warrant To Offering Pheromone Sciences Corp Adds Half Warrant To Offering


Pheromone Sciences Corp. (CDNX:PHS) today announced that its recently announced $2.2 million special warrant private placement has been amended, subject to regulatory approval, to provide that each special warrant of the Company will be exercisable, at no additional consideration, into one common share and one-half of a warrant. Each whole warrant will entitle the holder to purchase one common share of the Company at an exercise price of $1.25 per share for one year from closing anticipated for February, 2001.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 13, 2001 13 February, 2001

Benoit La Salle Joins Pheromone Sciences Board of Directors Benoit La Salle Joins Pheromone Sciences Board of Directors


Toronto, Ontario (February 13, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Benoit La Salle to its Board of Directors

Mr. La Salle, a Chartered Accountant, is a member of the Quebec Order of Chartered Accountants, the Canadian Institute of Chartered Accountants, the Order of Chartered Administrators of Quebec and the Quebec Institute of Financial Planners. In 1980, Mr. La Salle founded the firm of Grou, La Salle & Associes, Chartered Accountants. Mr. La Salle holds extensive experience in matters relating to public companies.

Active in the public markets, Mr. La Salle is currently the President and Chief Executive Officer of Semafo Inc., a TSE listing firm engaged in mining activities in West Africa. In addition, he serves on the board of directors of a number of public companies including Bio-Capital and Bridgepoint International Inc. and as both a member of the board of directors and audit committee of The Canam Manac Group, Vasogen Inc., Pebercan Inc., and Electromed Imaging Inc.

"We are delighted to have Benoit La Salle accept a position on the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Mr. La Salle adds extensive business experience and financial expertise that will benefit the Company as we continue to advance the commercial development of our products."

Mr. La Salle holds a commerce degree from McGill University and a master of business administration from IMEDE in Switzerland. He is involved in a number of charitable organizations including that of the Ecole Buissoniere Foundation and Foster Parents Plan Canada.

The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Douglas Marett. Mr. Marett remains a member of senior management retaining the position Vice- President and Chief Scientific Officer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 08, 2001 8 February, 2001

Pheromone Sciences Corp Announces U.S. Clinical Trials


Toronto, Ontario (February 8, 2001) - Pheromone Sciences Corp (CDNX: PHS), today announced plans for a multi-center U.S. based clinical trial of its PSC Fertility Monitor™. The trial will be carried out at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Comprising 140 patients, the trial will compare the efficacy of the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ to current techniques for detecting fertility and ovulation. Subject to regulatory approval, patient recruitment is scheduled to commence in April and conclude in Q-4.

U.S. clinical trial plans are being undertaken on the heels of positive clinical results obtained from a pilot trial conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The Canadian trial demonstrated that the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

Commenting on the U.S. trial program Duke University's Dr. Haney stated, "We look forward to being involved in a clinical study that can potentially assist women in better knowing when fertility and ovulation are optimum". Dr. Corson of the Thomas Jefferson University Hospital added, "Obtaining results in line with those at the Toronto General Hospital would point to the PSC Fertility Monitor™ becoming a valuable tool in planning conception."

The PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ offers a new user- friendly option in family planning. The product, housed in a wristwatch-like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ is a proprietary, non- invasive device, which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor and predicts the status of the user as being not-fertile, fertile or ovulating.

"We remain committed to our goal of filing regulatory submissions with the FDA for marketing approval on the PSC Fertility MonitorÃ?��Ã?¯Ã?¿Ã?½Ã?ï¿ ½Ã?¯Ã?�Ã?¿Ã?�Ã?½Ã?�ï¿ ½Ã?�Ã?¯Ã?��Ã?�Ã?¿à ?��Ã?�Ã?½Ã?��Ã? ¯Ã?¿ Ã?½Ã?��Ã?�Ã?¯Ã?�ï¿ ½Ã?¯Ã?¿Ã?½Ã?��Ã?�à ?¿Ã? ��Ã?¯Ã?¿Ã?½Ã?��à ?�Ã?½Ã?��Ã?¯Ã?¿Ã?½ Ã?� Ã?¯Ã?�Ã?¿ Ã?�Ã?½Ã?��Ã?¯Ã?¿Ã? ½Ã?��Ã?�Ã?¯Ã?��à ?¯Ã?¿ Ã?½Ã?�Ã?¯Ã?�Ã?¿Ã?�Ã? ½Ã?��Ã?¯Ã?¿Ã?½Ã?�½Ã? �Ã?¿Ã?� �Ã?¯Ã?¿Ã?½Ã?�Ã?¯Ã?� Ã?¿Ã?�Ã?½Ã?��Ã?¯Ã? ¿Ã?½Ã? ��Ã?�Ã?½ prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "In tandem with the clinical trial process we also intend to advance efforts aimed at concluding a strategic alliance for product marketing and distribution rights."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 22, 2001 22 January, 2001

Pheromone Sciences Corp. Announces Private Placement Offering


Pheromone Sciences Corp. (CDNX:PHS) today announced that, subject to regulatory approval, it intends to offer for sale, via private placement, up to 2,200,000 special warrants of the Company at an issue price of $1.00 per special warrant. Each special warrant will be exercisable, at no additional consideration, into one common share of the Company.

The private placement is scheduled to close in February, 2001.

Following closing, the Company will file a prospectus to qualify the distribution of the common shares issuable upon exercise of the special warrants.

Proceeds of the offering will be used to support the Company's research and development program, ongoing operations, and business development.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 17, 2001 17 January, 2001

Pheromone Sciences Corp Announces Positive Clinical Trial Results


Pheromone Sciences Corp (CDNX:PHS), today announced positive clinical trial results on its lead product, the PSC Fertility Monitor'. The trial was conducted with 21 normal healthy women at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial compared the efficacy of the PSC Fertility Monitor' to current techniques for detecting fertility and ovulation. Results confirmed that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date, while also providing women with up to four days advance notice of ovulation. This accuracy compares very favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

In commenting on the outcome, Dr. Casper stated, "The results of this trial suggest that the PSC Fertility Monitor' represents a major advance in the field of fertility and ovulation prediction. The PSC Fertility Monitor' provides more advance notice than other available methods with reliable accuracy, in a convenient, non-invasive manner. This would also provide a new tool for couples engaged in family planning".

The PSC Fertility Monitor' offers a new user- friendly option in family planning. This product, which is housed in a modern styled wristwatch like device with an LCD readout, is worn at night during sleeping hours. The PSC Fertility Monitor' is a proprietary, non-invasive device which predicts ovulation by measuring ion changes on the surface of the skin. The device incorporates an interactive microprocessor combined with a biosensor enabling it to take up to 12 daily measurements from the skin surface and to evaluate the data in order to predict the status of the user as being not-fertile, fertile or ovulating. Results can be viewed at any time on the LCD screen of the device or as a computer- generated graphical printout for medical professionals.

"This is another significant milestone successfully achieved," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "We remain committed to our goal of completing U.S. regulatory submissions and concluding a strategic alliance for the marketing and distribution rights for this product come year end."

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

443 King Street East Toronto, Ont, Canada M5A 1L5 tel: (416) 861-9854 fax: (416) 861-9950

INVESTOR CONTACT Lorne Woods 1-(800) 937-3095

Nick Borrelly (604) 872-2012 mailto:investor@pheromonesciences.com http://www.pheromonesciences.com